Sanigen (188260.KQ) Stock

188260.KQ logo

Sanigen

188260.KQSouth Korea
Healthcare

Company profile

Sanigen reported revenue of 15.35 billion KRW for fiscal year 2025, and a net loss of 5.82 billion KRW. That is a net profit margin of -37.9% for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 22.27 billion KRW in fiscal year 2023 to 15.35 billion KRW in fiscal year 2025, 17.0% a year on average.

What stands out

  • It reported a net loss in each of its last 5 fiscal years (2021 to 2025).
  • Revenue fell 36.1% in fiscal year 2025, from 24.01 billion KRW in fiscal year 2024, after a rise of 7.8% the year before.
  • Its net profit margin over the last four reported quarters was -27.4%, against a median of -2.5% for 6 listed companies of similar size in its industry.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Sanigen

Sanigen Co. Ltd, a food sanitation and safety specialist, develops and services solutions for safe food manufacturing, distribution, and sales in Korea and internationally. The company offers PCR detection and nucleic acid extraction kits; bag, diluent, beam template, macroswab, and squeeze products; pathogen detection NGS panel kits; and hand sanitizers, vomit clean up kits, and pure systems. It also provides Microbial, physicochemical analysis, and food sanitation/lab services. Sanigen Co. Ltd was founded in 2005 and is headquartered in Anyang-si, South Korea.

Largest shareholders

  • Jung-Woong Park15.78 %15.78%

Share of the company, as of September 25, 2026

Leadership

  • Park Jeong Woong — Chairman & CEO, 56
  • Gyeong-il Jeon — Sales Director & Director, 48
  • Jong-wook Bang — Executive Director, 52
  • SungJin Sim — Head of Management Support Division & Executive Director, 43
  • SiBeom Song — Head of Production Division & Executive Director, 50

How much revenue does Sanigen make?

Sanigen reported 15.35 billion KRW in revenue for fiscal year 2025, down 36.1% from 24.01 billion KRW in fiscal year 2024.

What companies are similar to Sanigen?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Myungmoon Pharm co.,Ltd (017180.KS), Bcworld Pharm. Co., Ltd. (200780.KQ), Korea Arlico Pharm Co.,Ltd. (260660.KQ), Aprogen Biologics Inc. (003060.KS).

Has Sanigen made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 4.28 billion KRW; FY2022, a loss of 4.06 billion KRW; FY2023, a loss of 8.78 billion KRW; FY2024, a loss of 5.07 billion KRW; FY2025, a loss of 5.82 billion KRW. It reported a net loss in each of these 5 years.

How has Sanigen's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 25.22 billion KRW; FY2022, 26.76 billion KRW; FY2023, 22.27 billion KRW; FY2024, 24.01 billion KRW; FY2025, 15.35 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersAnyang-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Pyeongchon Digital Empire Building 411, Anyang-si, 14059
Phone
82 1 833 8010
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Sanigen (188260.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/188260.KQ

LinkedInLinkedInXXYouTubeYouTube